Biophore India Pharmaceuticals Pvt. Ltd. - Comprehensive Analysis Report
Summary
Biophore India Pharmaceuticals Pvt. Ltd. is a global, research-driven pharmaceutical company established in 2007. Specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), the company's core mission is to be a reliable knowledge-based firm in the API sector, driven by a customer-focused approach. Biophore is significant in the pharmaceutical industry for its strategic focus on niche and complex APIs, including Oncology APIs, MRI Contrast Agents, Peptides, Hormonals, and Injectable APIs. The company stands out for its strong R&D capabilities, regulatory compliance with global authorities like the US FDA and EU, and a consistent track record as a top DMF filer.
1. Strategic Focus & Objectives
Core Objectives
Biophore's main business objectives revolve around innovation, quality, and strategic growth within the global generic industry.
- Knowledge-based Leadership: Aim to be among the most reliable knowledge-based firms in the API sector.
- Customer-Focused Approach: Prioritize customer needs and satisfaction in all operations.
- Innovation and Quality: Continuously develop and manufacture high-quality, complex APIs.
- Global Generic Market Dominance: Focus on the development and manufacturing of niche and complex APIs for the global generic industry.
- Intellectual Property Protection: Develop non-infringing routes for bulk actives and intermediates, and APIs for NCE-1 filings.
- Regulatory Compliance: Maintain rigorous compliance with international regulatory standards such as US FDA and EU cGMP.
Specialization Areas
Biophore's expertise lies in several specialized therapeutic categories:
- Oncology APIs: Development and manufacturing of active ingredients for cancer treatments.
- MRI Contrast Agents: Production of specialized APIs used in magnetic resonance imaging.
- Peptides: Expertise in peptide synthesis and manufacturing.
- Hormonals: Production of hormonal active pharmaceutical ingredients.
- Injectable APIs: Manufacturing APIs suitable for injectable drug formulations.
- Complex Chemistry: Focus on difficult-to-synthesize and niche APIs with high entry barriers.
Unique value propositions include a strong emphasis on precision research and manufacturing, robust quality systems, and a consistent history of global regulatory approvals, differentiating them in the competitive API market.
Target Markets
Biophore primarily targets the global generic industry, focusing on segments where demand for niche, complex, and high-quality APIs is prevalent. Their market positioning strategy involves specializing in products that require advanced research and development capabilities, thereby addressing markets with high entry barriers. The company caters to both regulated markets, evidenced by its US FDA and EU approvals, and other international (ROW) markets.
2. Financial Overview
Funding History
Biophore India Pharmaceuticals Private Limited has raised a total funding of $2.74M across 3 rounds.
- Latest Funding Round: February 5, 2014, a Seed round of $990K.
- Lead Investor: Ontario
- Fund Utilization: The funding has supported the company's research, development, and manufacturing scale-up initiatives to expand its API portfolio and global reach.
- Impact on Company Growth: The investment contributed to Biophore's expansion, enabling the development of advanced facilities and a robust product pipeline. The company's post-money valuation as of this round was ₹105 Cr.
Current ownership structure indicates founders own 43.63%, enterprises own 20.00%, angels own 4.98%, and other individuals own 31.39%.
For the financial year ending March 31, 2024, Biophore generated a revenue of ₹386 Cr (approximately $46.7M), demonstrating a compounded annual growth rate (CAGR) of 15% in the last year. The operating revenue range is between INR 100 Cr - 500 Cr. The authorized share capital is INR 15.00 Cr, and the total paid-up capital is INR 1.06 Cr. For the financial year ended 2023, the company reported a minor revenue drop of 6.69%, but profit increased by 43.88%, and net worth increased by 35.97%.
3. Product Pipeline
Key Products/Services
Biophore continually expands its product range through internal R&D, process development, technology transfers, joint ventures, and collaborations. The company maintains a robust pipeline, with over 40 projects actively in the development stage at any given time.
Their product portfolio and development areas include:
- Comprehensive Generic APIs and Intermediates: A wide array of readily available products serving various therapeutic needs.
- Oncology: Active ingredients for cancer therapies, an area of high strategic focus.
- Contrast Media: APIs for diagnostic imaging applications, particularly MRI contrast agents.
- Peptides: Specialized active pharmaceutical ingredients with complex synthesis requirements.
- Hormonals: APIs for hormonal treatments.
- Injectables: APIs designed for injectable drug formulations, often requiring high purity standards.
Biophore's development strategy is geared towards expanding its presence in these complex and niche categories, ensuring a continuous flow of new, high-quality APIs into the global market. While specific timelines for individual products are not detailed, the ongoing 40+ projects indicate a steady and active development process.
4. Technology & Innovation
Technology Stack
Biophore's core strength is underpinned by its advanced research and development capabilities and specialized manufacturing infrastructure.
- Dedicated R&D Facilities: Two state-of-the-art R&D facilities located in Hyderabad and Vishakhapatnam.
- Robust Equipment: Equipped with advanced instruments from the USA, designed for research from milligram to kilogram scale. These include:
- 40 fume hoods for diverse chemical reactions.
- Walk-in hoods for kilo-scale synthesis.
- Dedicated hydrogenation rooms and Parr Hydrogenators.
- Buchi/Labconoco Rotavaps for efficient solvent removal.
- Glove boxes for handling sensitive or highly potent materials under contained conditions.
- Proprietary Developments & Methodologies:
- Non-infringing Routes of Synthesis: Development of unique, non-patented process routes for bulk actives and intermediates, crucial for generic pharmaceutical competition.
- Customized Manufacturing Units: Specialized units within facilities for the manufacture of complex APIs such as peptides, hormones, colored APIs, oncology drugs, and high-potent drug products, ensuring specialized handling and containment.
- Process Optimization and Validation: Strong emphasis on optimizing API manufacturing processes and validating methods to ensure product quality and scalability.
- Intellectual Property: A significant focus on patents and Drug Master Files (DMFs). Biophore holds over 50 patents and has filed more than 90 US DMFs and over 120 global DMFs, consistently ranking among the top DMF filers globally.
5. Leadership & Management
Executive Team
Biophore's leadership team is composed of seasoned professionals with deep expertise in pharmaceutical research, development, and operations.
- Dr. Jagadeesh Babu Rangisetty, Ph.D. - Founder & CEO:
- Professional Background: Holds an M.Pharm and Ph.D. from BITS, Pilani, and completed Post-Doc research at VCU, Virginia, USA. He has over 32 years of research experience.
- Notable Achievements & Key Contributions: Attributed with more than 150 patents and publications. He previously served as a Director of a lab at VCU and was Vice-President and co-founder of Navinta LLC. Dr. Rangisetty has been instrumental in developing complex APIs, including Iron-Sucrose and Sodium Ferric Gluconate complexes, and APIs for Para-IV filings. His vision has driven Biophore's strategic focus on niche and complex APIs.
- Dr. Manik Reddy Pullagurla, Ph.D. - Co-Founder & CSO:
- Professional Background: Holds a B.Pharm from BITS, Pilani, a Ph.D. from VCU, Virginia, USA, and completed Post-Doc research at VCU and UGA, Georgia. He has over 23 years of research experience.
- Notable Achievements & Key Contributions: Also associated with more than 150 patents and publications. He previously worked at Navinta LLC and Hospira. Dr. Pullagurla leads the company's scientific strategy and research initiatives, ensuring a robust pipeline of innovative and complex APIs.
- Ramesh K. - COO:
- Professional Background: A Mechanical Engineer with an MBA in Operations Management from Narsee Monjee Institute of Management, Mumbai. He brings over three decades of diversified industry experience.
- Notable Achievements & Key Contributions: Formerly CEO of Vijayasri Organics. As COO, Ramesh K. is responsible for overseeing Biophore's extensive manufacturing and operational processes, ensuring efficiency, quality, and regulatory compliance across its facilities.
- Deepak Khanna - Associate Vice President - API Business Development:
- Kumar Kothapalli (K.K.) - Chief Medical Officer:
The board of directors includes Jagadeesh Babu Rangisetty, Manik Reddy Pullagurla, Ramprasad Nimmagadda, Madhusudan Rao Kothapalli, and Harcharan Singh.
Recent Leadership Changes
Information on specific recent leadership changes is not detailed in the provided data. The existing leadership team remains consistent, indicating stability in key executive roles.
6. Talent and Growth Indicators
Hiring Trends and Workforce
As of August 31, 2025, Biophore India Pharmaceuticals Pvt. Ltd. has a team size of 664 employees, having experienced a 23% growth in its employee count over the past year. This significant increase highlights the company's expansion and investment in its workforce.
Key roles being recruited and current hiring patterns indicate a continuous demand for expertise across research, development, and quality control:
- API Synthesis R&D: Recruitment for Trainees (M.Sc Analytical/Organic Chemistry with 0-1 year experience) and Research Chemists/Executives/Sr. Executives (M.Sc Analytical/Organic Chemistry with 2-8 years experience). These roles focus on process optimization, lab validation, impurity synthesis, DMF deficiency resolution, and technology transfer.
- Scientific Research & Development (SRD) / Analytical Research & Development (ARD): Opportunities for Chemists/Executives/Sr. Executives (M.Sc. Chemistry or relevant with 2-8 years experience) to handle analytical method development, validation, and instrument operation (HPLC, GC, Dissolution, UV).
- Formulation AR&D & R&D: Positions for Executive & Research Analysts (M.Sc / B.Pharm / M.Pharm with 2-7 years experience) focusing on analytical method development/validation, routine
